文献速递慢性肾脏病肾血管病与高血压

促红细胞生成素刺激剂是否等效?

Are all erythropoiesis-stimulating agents created equal?
PubMed 文献 · Nephrol Dial Transplant · 2021-01-01

本文综述了不同促红细胞生成素刺激剂(ESA)在药代动力学、药效学及受体激活方式上的差异,指出高Hb靶目标剂量与心血管事件、死亡和癌症风险增加相关。比较不同ESA分子疗效/安全性的证据有限,近期观察性研究与随机对照试验结果矛盾,而随机对照试验因减少适应症偏倚和混杂因素提供更高证据级别。新型PHD抑制剂口服、多靶点作用,可能对炎症伴功能性缺铁患者更有效,但不同PHD抑制剂间也存在差异。

要点

  • 不同ESA分子药代动力学和药效学特征不同,可能影响疗效与安全性。
  • 高Hb靶目标剂量的ESA使用与心血管事件、死亡和癌症风险增加相关。
  • 新型PHD抑制剂口服、多靶点,可能对炎症伴功能性缺铁患者更有效。

核心结论

  • 不同ESA分子可能具有不同的疗效/安全性特征,但现有证据有限且矛盾。
  • 随机对照试验因减少偏倚和混杂,提供比观察性研究更高证据级别。
  • PHD抑制剂与现有ESA作用机制不同,可能对特定人群更有效,但不同PHD抑制剂间也可能存在差异。

研究设计与样本

  • 本文为综述,未报告系统检索范围。
  • 文中提及一项观察性研究和一项随机对照试验,但未报告样本量等具体设计细节。

主要发现

  • 高Hb靶目标剂量的ESA使用与心血管不良事件、死亡和癌症风险增加相关。
  • 不同ESA分子虽作用机制相同,但药代动力学和药效学特征不同,可能影响下游事件。
  • 观察性研究与随机对照试验在比较不同ESA类型时结果矛盾,患者特征和ESA分子存在差异。
  • PHD抑制剂口服,模拟缺氧稳定HIFα,多靶点作用包括刺激内源性EPO合成、铁动员/吸收和降低hepcidin。
  • 不同PHD抑制剂分子结构和对三种PHD亚型选择性不同,疗效和安全性可能不同。

临床怎么用

  • 临床应避免使用高剂量ESA追求高Hb靶目标,以降低心血管事件、死亡和癌症风险。
  • 选择ESA类型时需考虑分子间药代动力学和药效学差异,但现有比较证据有限。
  • 对炎症伴功能性缺铁患者,PHD抑制剂可能更具优势,但需注意不同PHD抑制剂间的差异。

局限性

  • 不同ESA类型比较的随机对照试验证据有限,观察性研究存在适应症偏倚和混杂。
  • PHD抑制剂的疗效和安全性尚未与现有ESA进行充分比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Erythropoiesis-stimulating agents (ESAs) are effective drugs to correct and maintain haemoglobin (Hb) levels, however, their use at doses to reach high Hb targets has been associated with an increased risk of cardiovascular adverse events, mortality and cancer. Presently used ESAs have a common mechanism of action but different pharmacokinetic and pharmacodynamic characteristics. Accordingly, the mode of activation of the erythropoietin (EPO) receptor can exert marked differences in downstream events. It is unknown whether the various ESA molecules have different efficacy/safety profiles. The relative mortality and morbidity risks associated with the use of different types of ESAs remains poorly evaluated. Recently an observational study and a randomized clinical trial provided conflicting results regarding this matter. However, these two studies displayed several differences in patient characteristics and ESA molecules used. More importantly, by definition, randomized clinical trials avoid bias by indication and suffer less from confounding factors. Therefore they bring a higher degree of evidence. The scenario becomes even more complex when considering the new class of ESAs, called prolyl-hydroxylase domain (PHD) inhibitors. They are oral drugs that mimic exposure to hypoxia and stabilize hypoxia-inducible factor α. They profoundly differ from presently used ESAs, as they have multiple targets of action, including the stimulation of endogenous EPO synthesis, direct mobilization/absorption of iron and a higher reduction of hepcidin. Accordingly, they have the potential to be more effective in inflamed patients with functional iron deficiency, i.e. the setting of patients who are at higher risk of cardiovascular events and mortality in response to present ESA use. As for ESAs, individual PHD inhibitors differ in molecular structure and degree of selectivity for the three main PHD isoforms; their efficacy and safety profiles may therefore be different from that of presently available ESAs.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Locatelli F, Del Vecchio L, De Nicola L, et al. Are all erythropoiesis-stimulating agents created equal? Nephrol Dial Transplant. 2021. PMID: 32206785. doi:10.1093/ndt/gfaa034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。